Skye Bioscience (SKYE) CMO receives 125,000 stock options at $0.82 exercise price

Rhea-AI Filing Summary

Skye Bioscience Chief Medical Officer granted stock options. On February 6, 2026, Chief Medical Officer Puneet S. Arora received a stock option to buy 125,000 shares of Skye Bioscience common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over four years beginning January 19, 2026, and is held directly by the reporting person.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Arora Puneet S.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arora Puneet S.

(Last) (First) (Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		125,000		(1)	02/06/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Skye Bioscience (SKYE) report for its CMO?

Skye Bioscience reported that Chief Medical Officer Puneet S. Arora received a stock option grant for 125,000 shares on February 6, 2026. The option gives the right to purchase common stock at a fixed exercise price over time.

How many Skye Bioscience (SKYE) shares are covered by the new stock option?

The stock option granted to Chief Medical Officer Puneet S. Arora covers 125,000 shares of Skye Bioscience common stock. These underlying shares can potentially be acquired through future exercises of the option, subject to the stated vesting schedule and option terms.

What is the exercise price of the Skye Bioscience (SKYE) stock option granted to the CMO?

The stock option granted to Chief Medical Officer Puneet S. Arora has an exercise price of $0.82 per share. This means each underlying Skye Bioscience common share can be purchased for $0.82 when vested and if the option is exercised.

How does the Skye Bioscience (SKYE) CMO stock option vest over time?

The stock option granted to Chief Medical Officer Puneet S. Arora vests in equal monthly installments over a four-year period. Vesting begins on January 19, 2026, gradually increasing the number of option shares that become exercisable each month.

How many Skye Bioscience (SKYE) derivative securities does the CMO hold after this transaction?

After this transaction, Chief Medical Officer Puneet S. Arora beneficially owns 125,000 derivative securities in the form of stock options. These options relate to Skye Bioscience common stock and are reported as directly owned in the filing.

Is the Skye Bioscience (SKYE) CMO stock option held directly or indirectly?

The Form 4 indicates that the 125,000 stock options granted to Chief Medical Officer Puneet S. Arora are held directly. There is no referenced intermediary entity or indirect ownership structure in the reported transaction details.